BDTX
Income statement / Annual
Last year (2024), Black Diamond Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Black Diamond Therapeutics, Inc.'s net income was -$69.68 M.
See Black Diamond Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$437.00 K
|
$0.00
|
$0.00
|
$0.00
|
$47.00 K
|
$44.00 K
|
$24.00 K
|
| Gross Profit |
$0.00
|
-$437.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$47.00 K
|
-$44.00 K
|
-$24.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$51.31 M
|
$58.91 M
|
$64.44 M
|
$96.83 M
|
$48.21 M
|
$21.75 M
|
$6.95 M
|
$3.45 M
|
| General & Administrative Expenses |
$27.47 M
|
$27.11 M
|
$28.39 M
|
$30.04 M
|
$21.36 M
|
$7.58 M
|
$1.95 M
|
$666.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$27.47 M
|
$27.11 M
|
$28.39 M
|
$30.04 M
|
$21.36 M
|
$7.58 M
|
$1.95 M
|
$666.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$16.00 K
|
-$6.00 K
|
| Operating Expenses |
$78.78 M
|
$86.02 M
|
$92.83 M
|
$126.87 M
|
$69.57 M
|
$29.33 M
|
$8.90 M
|
$4.12 M
|
| Cost And Expenses |
$78.78 M
|
$86.46 M
|
$92.83 M
|
$126.87 M
|
$69.57 M
|
$29.33 M
|
$8.90 M
|
$4.12 M
|
| Interest Income |
$2.18 M
|
$1.92 M
|
$2.03 M
|
$3.46 M
|
$4.04 M
|
$461.00 K
|
$4.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.00 K
|
$0.00
|
$0.00
|
$65.00 K
|
| Depreciation & Amortization |
$343.00 K
|
$437.00 K
|
$508.00 K
|
$205.00 K
|
$600.00 K
|
$47.00 K
|
$44.00 K
|
$24.00 K
|
| EBITDA |
-$78.44 M |
-$86.02 M |
-$92.32 M |
-$126.67 M |
-$66.65 M |
-$29.29 M |
-$8.89 M |
-$4.10 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$9.11 M
|
$4.02 M
|
$1.66 M
|
$1.28 M
|
$2.32 M
|
-$5.93 M
|
-$27.00 K
|
-$483.00 K
|
| Income Before Tax |
-$69.68 M
|
-$82.44 M
|
-$91.17 M
|
-$125.60 M
|
-$67.25 M
|
-$35.26 M
|
-$8.93 M
|
-$4.60 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$27.00 K
|
$0.00
|
| Net Income |
-$69.68 M
|
-$82.44 M
|
-$91.17 M
|
-$125.60 M
|
-$67.25 M
|
-$35.26 M
|
-$8.93 M
|
-$4.60 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.27 |
-1.88 |
-2.52 |
-3.47 |
-2.04 |
-1.15 |
-0.64 |
-0.64 |
| EPS Diluted |
-1.27 |
-1.88 |
-2.52 |
-3.47 |
-2.04 |
-1.15 |
-0.64 |
-0.64 |
| Weighted Average Shares Out |
$55.03 M
|
$43.95 M
|
$36.23 M
|
$36.19 M
|
$32.91 M
|
$35.91 M
|
$13.95 M
|
$7.20 M
|
| Weighted Average Shares Out Diluted |
$55.03 M
|
$43.95 M
|
$36.23 M
|
$36.19 M
|
$32.91 M
|
$35.91 M
|
$13.95 M
|
$7.20 M
|
| Link |
|
|
|
|
|
|
|
|
